Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug CRB-913 enters human testing

NCT ID NCT07310901

Disease control Sponsor: Corbus Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CRB-913 for weight loss in people with obesity. It involves 252 participants and has two parts: first, measuring how the drug works in healthy adults, then comparing three doses against a placebo over 12 weeks. The goal is to check safety and how the drug affects body weight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CRB-913
What this could lead to
If successful, this could lead to a new weight-loss medication for people with obesity.
What could go wrong
This is an early Phase 1b trial, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 252 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Part 1: Participants with BMI 18.0-25.0 kg/m² * Part 2: Obese participants with BMI ≥30 kg/m² Exclusion Criteria: * Significant liver disease or moderate-severe hepatic impairment * History of seizures, epilepsy, or intracranial surgery * Diabetes mellitus (Type 1 or Type 2), except gestational * Bariatric surgery or \>5 kg weight change in past 3 months * Recent use (within 3 months) of GLP-1 agonists or other weight-loss medications * Major depression within 2 years. * Any history of suicidal ideation/attempt * Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) * Elevated screening scores: PHQ-9 \>4, GAD-7 \>4, or positive C-SSRS Items 1-2 * Active or recent (within 5 years) malignancy (exceptions: in situ and fully resected nonmelanoma skin cancer) * Abnormal thyroid function: TSH \>6 mIU/L unless stable on replacement therapy * QTc \>470 msec (females) or \>450 msec (males) or history of long QT syndrome * Use of systemic corticosteroids or unstable chronic medications affecting BP, lipids, or glucose * Use of CYP3A4 substrates or strong P-gp substrates/inhibitors * Investigational drug use within 28 days * Prior exposure to CRB-913 or other CB1 inverse agonists/antagonists * Substance abuse history * Pregnancy, breastfeeding, or unwillingness to use highly effective contraception * Positive drug or alcohol screen * Any condition that, in the investigator's judgment, makes participation unsafe or non-feasible

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese but otherwise healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Body Weight endocrine system disorder metabolic disease Nutritional and Metabolic Diseases nutritional disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese but otherwise healthy participants

Contacts and locations

Locations

  • Accel Research Sites

    DeLand, Florida, 32720, United States

  • Alliance Clinical

    Las Vegas, Nevada, 89109, United States

  • Arizona Clinical Trials

    Chandler, Arizona, 85225, United States

  • Central Alabama Research

    Birmingham, Alabama, 35209, United States

  • Flourish Research

    San Antonio, Texas, 78229, United States

  • Louisville Metabolic and Atherosclerosis Research Center

    Louisville, Kentucky, 40213, United States

  • Lucas Research

    Morehead City, North Carolina, 28557, United States

  • Medpace Clinical Pharmacology

    Cincinnati, Ohio, 45227, United States

  • Neurobehavioral Research

    Cedarhurst, New York, 11516, United States

  • Prospective Research Innovations

    Rancho Cucamonga, California, 91730, United States

  • Quotient Sciences

    Miami, Florida, 33126, United States

  • Rochester Clinical Research

    Rochester, New York, 14609, United States

  • Tampa Bay Medical Research

    Largo, Florida, 33761, United States

  • Velocity Clinical Research

    Cleveland, Ohio, 44122, United States

  • Velocity Clinical Research

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.